Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.
- DOI
- 10.1007/s00520-025-10182-9
- Published
- 2025-11-26
- Container
- Support Care Cancer
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00520-025-10182-9,
title = {Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.},
author = {Brown R and Smith KE and Shanshal MM and Dimou A and Leventakos K and Parikh K and Mansfield AS and Molina JR and Goetz MP and Jatoi A and Cathcart-Rake E.},
year = {2025},
journal = {Support Care Cancer},
doi = {10.1007/s00520-025-10182-9},
url = {https://doi.org/10.1007/s00520-025-10182-9}
}RIS
TY - JOUR TI - Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support. AU - Brown R AU - Smith KE AU - Shanshal MM AU - Dimou A AU - Leventakos K AU - Parikh K AU - Mansfield AS AU - Molina JR AU - Goetz MP AU - Jatoi A AU - Cathcart-Rake E. PY - 2025 JO - Support Care Cancer DO - 10.1007/s00520-025-10182-9 UR - https://doi.org/10.1007/s00520-025-10182-9 ER -
APA
R, B., KE, S., MM, S., A, D., K, L., K, P., AS, M., JR, M., MP, G., A, J., & E., C. (2025). Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.. Support Care Cancer. https://doi.org/10.1007/s00520-025-10182-9
Source records
- europe-pmc · retrieved 2026-09-26T13:46:10.674Z